|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/28 | |||
| A61P 35/00 | |||
| A61P 37/00 |
| (11) | Patento numeris | 3154581 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15747597.1 |
| Europos patento paraiškos padavimo data | 2015-06-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-04-19 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-02-20 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/035832 |
| Data | 2015-06-15 |
| (87) | Numeris | WO 2015/195556 |
| Data | 2015-12-23 |
| (30) | Numeris | Data | Šalis |
| 201462012864 P | 2014-06-16 | US |
| (72) |
CHILDS, Richard, W., US
BERG, Maria, US
CALDERON, Luis, Espinoza, US
SASSER, Kate, US
ATTAR, Ricardo, US
|
| (73) |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services,
National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard Suite 325 MSC 7660, Bethesda, MD 20852-7660,
US
Janssen Biotech, Inc., 1400 Mckean Road, Spring House, PA 19477, US |
| (54) | BLOCKING CD38 USING ANTI-CD38 F(AB`)2 TO PROTECT NK CELLS |
| BLOCKING CD38 USING ANTI-CD38 F(AB`)2 TO PROTECT NK CELLS |